DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2080
INDEX
Trospium chloride, 231, 232, 232t
True end points, surrogate vs., 9
TRUSOPT (dorzolamide), 680
Trypan blue, 1788
Trypanosomiasis, 1421–1423
Tryptamine, 225
Tubal ligation, one-year failure rate,
1834t
Tuberculosis
drug resistance in, 1565
principles of therapy, 1564–1565
prophylaxis, 1564–1565
tumor necrosis factor (TNF)
inhibitors and, 1826–1827
Tubocurarine
central nervous system and, 261
decamethonium vs., 267–268
histamine and, 914
structure of, 259f
d-tubucurarine, cholinergic receptors
and, 206t
Tubuloglomerular feedback, 673
Tumor lysis syndrome, 1746–1747
Tumor necrosis factor (TNF)
in inflammation, 960, 961
in rheumatoid arthritis, 960, 961
Tumor necrosis factor (TNF) inhibitors
adverse effects and side effects of,
1826
for psoriasis, 1825–1827
Tumor necrosis factor (TNF) receptors,
63
TUMS-EX, 1316t
Turner’s syndrome, failure of ovarian
development in, treatment of,
1838
Twin studies, 145–146, 146f
TYKERB (lapatinib), 1737–1738
TYLENOL (acetaminophen), 982–984
Tyloxapol, 1798
Type II nuclear receptors, 97
Typhoid fever, 1527–1528
Tyramine
adrenergic receptors and, 206t
norephinephrine transporter and, 198
structure of, 279t
tachyphylaxis and, 199
Tyrosine hydroxylase
in catecholamine synthesis, 194f,
195t
deficiency, 195
Tyrosine kinase(s), 60–61, 1731–1732.
See also Protein tyrosine
kinase inhibitors
Tyrosine kinase growth factor
receptors, 1744, 1744f
U
U50,488, actions and selectivities, 485t
U69,587, actions and selectivities, 485t
UCSC Genome Browser, 153t
UDP-glucoronic acid (UDP-GA), 132
UDP-glucuronosyltransferases (UGT)
haplotype blocks, 125t, 132, 149f
polymorphisms, 159t
UGT. See UDPglucuronosyltransferases
(UGT)
UGt1A1, 149f
Ulcer(s)
genital, in females, 1842t
NSAID-related, 1320–1321
stress-related, 1321
treatment of, 1319t
Ulcerative colitis (UC), biological
agents for, 1825t
ULESFIA (benzyl alcohol), 1819
ulipristal (ella, ellaOne), 1836t, 1837
ULTRACEF (cefadroxil), 1494t
“Ultra-rapid” metabolizers, 157, 1225t
ULTRAVATE (halbetasol propionate),
1808t
ULTRAVATE (halobetasol propionate
ointment), 1225t
Ultraviolet radiation, 1813
Uncompetitive inhibition, 96
Undecylenic acid, 1589, 1817
UNIVASC (moexipril), 733–734
Urapidil, 310
URAT-1, 998
Urate transporter 1 (URAT1), 114
Urea, 681
dermatolgic effects of, 1829
pharmacology of, 681t
structure of, 681t
UREAPHIL (urea), 681t
Uremic prurigo, thalidomide for, 1824
Ureter
in autonomic nervous system, 179t
opioids and, 498
Urethritis, in females, 1842t
Uricosuric agents, 998–1000
Urinary alkalinization, 85
Urinary bladder
ABC transporters in, 106t
acetylcholine and, 221–222
anticholinesterase agents for atony
of, 250
in autonomic nervous system, 179t
bethanechol and, 224
choline esters and, 223t
muscarinic antagonists and, 231
opioids and, 497
Urinary excretion
of common drugs, 1809t–1890t
as pharmacodynamic parameter,
1802–1803
Urinary tract
acetylcholine and, 221–222
muscarinic antagonists and, 229
sulfonamides and, 1467
Urinary tract infections
antiseptics and analgesics for,
1474–1475
drugs for
gentamicin, 1515
quinolones, 1473
TMP-SMX, 1469
sulfonamides for, 1467
Urine, excretion in, 26
Urodilatin, 695–696
Urokinase plasminogen activator
(u-PA), 852
Urticaria
H 1
receptor antagonists for, 922
warfarin-induced, 864
Urticaria, IVIG for, 1827
Urticarial vasculitis, dapsone for, 1823
Urticaria pigmentosa,
photochemotherapy for,
1814
User fees, paid to FDA, 9
Uterus
eicosanoids and, 950
opioids and, 498
UV. See Ultraviolet radiation
UVADEX (methoxsalen), 1814
Uveitis
causes, 1788
definition of, 1788
parasitic, 1783
V
Vaccines, 1023
VAChT. See Vesicular ACh transporter
(VAChT)
VAGIFEM (estradiol tabs), 1839t
Vaginal discharge, 1842t
Vaginal dryness, 1176
Vaginal ring, 1834, 1839t
Vagus nerve, 171, 173f, 174–175
Valacyclovir, 1593–1600, 1596t
absorption of, 1594–1596
antiviral activity of, 1593–1594
chemistry of, 1593–1594
for cutaneous viral infections, 1818
distribution of, 1594–1596
elimination of, 1594–1596
for genital herpes, 1842t